Ardelyx (ARDX) Firmly Above Resistance.
Were not traders and we don't do technical analysis, but we could see this coming from a mile away. Next stop $9.00...
Continued Strength at LQR House (LQR) Post-Reverse Split.
Like a Surprise Christmas Gift, LQR House has Gained Nearly Four-Fold (330%) Post Split. New Report out Tomorrow.
Five Myths About Ketamine and Matthew Perry’s Death (Fox News).
Through the first nine months of the year, global Johnson and Johnson's Spravato Ketamine nasal-spray revenues were $483 million, an 88.8%...
LQR House (LQR) +65%, Rebounding On New Clients Announcements.
The Liquor House Continues to Impress.
We called this the most interesting Company of 2023. While extreme volume...
We’re Up 35% in Paramount.
Market Cap Increases $3 Billion Since Adding to Watch List on October 23rd. And That's a Lot of Money!
Two That Doubled and Now Look Ready to Break Out.. and a Third That...
We are up 234% in Ardelyx (ARDX) $5.23 since adding it to Watch List a year ago and up 71% in Cardiol...
Tharimmune (THAR) Announces Positive Topline “Itching” Data.
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Phase...
Hundreds of Stocks Have Fallen Below $1. They’re Still Listed on Nasdaq. (WSJ)
Investor-protection advocates say many belong to risky small companies that should be on the OTC market.
With 557 names...
Selling Under Cash. LQR House (LQR) Addresses Nasdaq Delisting.
If You're a Sophisticated Speculator, and we do Mean Sophisticated, Study LQR House (LQR) or 'the Liquor House' Story.
LQR House (LQR). And the Numbers are In!
A Situation Which Can't be Ignored!
That's not to say run out and buy it, but this current valuation...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
